Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

4期已完成 NCT04655170

适应症	COPD Exacerbation
分期	4期
申办方	University of Tennessee Graduate School of Medicine
状态	已完成
受试者人数	60 人
干预（药物）	Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
开始日期	2020年12月9日
完成日期	2023年1月19日
结果公布日	2026年8月3日

摘要

The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.

Difference in Modified Borg Dyspnea Scale Scores Between Groups

From enrollment to the end of treatment at Day 7 · scores on a scale

Experimental: Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)	1.89 scores on a scale
Active Comparator: Group 2: Ipratropium Bromide (Atrovent) & Albuterol(Ventolin) as Standard of Care	1.92 scores on a scale

p-value	0.95

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics
Anti-Platelets in Chronic Obstructive Pulmonary Disease — Brigham and Women's Hospital

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский